Sign in
CompletedNo phase

SafeBoosC III Two-year Follow-up

Key facts

Who runs it
Gorm Greisen
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,601 people enrolled
Started
23 Sept 2021
Ended
19 Oct 2024
Type of study
Observational
Treatments tested
  • Treatment as usual + cerebral oximetry monitoring the first 72 hours of life
Record updated
7 November 2024

Who can take part

Age
12 months to 30 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Participation in the SafeBoosC-III trial and enrollment in a neonatal intensive care unit (NICU) taking part in the follow-up study, with parental consent according to local regulations

Who cannot take part

  • Parental objection to the use of their child's data in the follow-up study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The SafeBoosC-III 2 year follow up study will follow up on all patients randomised in the SafeBoosC-III clinical trial (NCT03770741). The investigators will collect data when the patients are two years of corrected age from routine standardised follow up assessments, parental questionnaires as well as informal assessments. The study will commence in September 2021, and will expect to include all 72 sites across 18 countries, which take part of the SafeBoosC-III clinical trial.

Treatments tested

  • Treatment as usual + cerebral oximetry monitoring the first 72 hours of life

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Cerebral Near-infrared Spectroscopy Monitoring Versus Treatment as Usual for Extremely Preterm Infants: a Protocol for the Follow-up Study for the SafeBoosC-III Trial
Record updated
7 November 2024